What’s next for drug pricing in the US? Proposals to alter antitrust and patent laws may signal a renewed focus on drug pricing by federal lawmakers, while the growing web of state laws is expected to increase compliance challenges for the pharmaceutical industry. What’s changing? A new package of proposed bills, announced in connection with an April 2021 US House of Representatives Judiciary Antitrust Subcommittee hearing on drug prices, may indicate that federal lawmakers are turning their competition focus to the

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.